47th EASD Annual Meeting - General Information

PROGRAMME

ORIGINAL COMMUNICATIONS are invited on any subject relevant to the understanding of diabetes mellitus.

THE CLOSING DATE FOR ABSTRACTS IS 01 APRIL 2011 23:59 hrs CET. Communications must be delivered in English. There is no simultaneous translation. The Provisional Programme will be sent to all paid-up members of EASD in June 2011.

The programme will include the 46th Minkowski Lecture, the 26th Camillo Golgi Lecture, the 43rd Claude Bernard Lecture given by Professor Ele Ferrannini, the 5th Albert Renold Prize Lecture for Outstanding Achievement in Research on the Islets of Langerhans, State of the Art Lectures, Symposia and Oral and Poster Presentations.

It is not permitted to take photographs and/or film during any of the sessions.

RECEIPT OF ABSTRACTS

Abstracts can only be submitted online and MUST be submitted BEFORE 01 APRIL 2011 23:59 hrs CET. THIS DEADLINE WILL BE STRICTLY ENFORCED, as will be the regulations given below. Acknowledgement of receipt will be sent via e-mail to the presenting (= first named) author. Please contact the EASD Office if no receipt of acknowledgement has been received by 10 April 2011.

SUBMISSION OF ABSTRACTS

The following is a brief overview of the abstract submission process. Please read carefully the DETAILED ABSTRACT SUBMISSION GUIDELINES before you begin the abstract submission process.

Authors are not permitted to submit work that they know is likely to be published before the EASD Annual Meeting. The Programme Committee has the right to withdraw an abstract from the programme containing material that has already been published. However, EASD will consider abstracts that have been presented in recent months at local or national diabetes meetings. An author submitting or presenting published work will be banned from presenting data at the EASD Meetings for three years.

Abstracts submitted on Human Studies:

The box must be marked stating that the study has been reviewed by the Local Ethics Committee and that it has therefore been performed in accordance with the ethical standards laid down in the Helsinki Declaration (see World Medical Association: www.wma.net).

Abstracts submitted on Animal Studies:

The box must be marked stating that the study has been carried out along the “Principles of laboratory animal care” (NIH Publication no. 85-23, revised 1985) and according to the national law, if applicable.

Selection of abstracts for the Scientific Programme is made anonymously. THE ABSTRACT MUST BE SUBMITTED as follows:

Each author can be listed ONLY ONCE as the presenting author (presenting author is always the first named author in the author block) on ONE (1) abstract. Each additional abstract will be removed from the system before being sent to the Review Committee. Presenting authors may be co-authors of other abstracts. It is MANDATORY that the first named  (= presenting) author of any abstract accepted for presentation be present to deliver his/her paper. Failure to do so, without prior or adequate explanation sent to the EASD Office by fax or e-mail, may result in the author or the institution being banned from presenting abstracts for the next three years.

Abstracts are welcome from non-members of EASD. Attention is drawn to the Registration section of this General Information, regarding the date by which authors must become members of EASD in order to qualify for preferential registration fees. These regulations will be strictly enforced.

The abstract must be submitted in English. New authors should create an account using a login name and a password. With this information they can revise the submission as often as required, make changes, additions, amendments, change/add/delete authors, copy special characters easily into the text, re-write the abstract, download the text from a file or copy it into the submission box. All this is possible until the Abstract Submission Deadline: 01 April 2011 23:59 hrs CET. After this date the account will be closed. CHANGES TO THE CONTENT OF THE SUBMITTED ABSTRACT WILL NOT BE ACCEPTED after the submission deadline.

The abstract should be submitted in the following way:

1)  The title should be short (maximum 160 characters).

2) Please enter your name and the names of co-authors as given in the following example. It is important to start each name with a capital letter and continue in lower case

Example:
First name:       Frederick
Initial:              G
Last name:       Banting

3) The abstract must be structured. Begin each section with the provided sub-headings in bold (Background and aims:, Materials and methods:, Results: and Conclusion:). The abstract structuring words are in the abstract text box (do not change them or delete them). One or two sentences should describe the methods, and any aspects of methodology (e.g. use of control groups, randomisation, patient selection, assay variation). The sentences stating the results must include hard data, including statistical analysis.

4)   References are not allowed.

5)   For drugs exclusively generic names should be used (no trademarks).

6)   A list of approved abbreviations and units of expression for use without definition appears in DIABETOLOGIA:

       http://www.diabetologia-journal.org/webpages/abbreviations.html  

7)   Grant/Support information must be entered into the special field.

8)   Where applicable, the Clinical Trial Registration Number must be entered.

9)   Only one keyword can be selected.

10)   Abstracts CANNOT be submitted as an e-mail attachment.

11) A signed copy of the final version of the abstract must be sent ONLY per e-mail as PDF file attachment to: abstracts(at)easd.org by 05 April 2011 23:59 hrs CET.  

In case of questions, please call: +49-211-75 84 69 0 or contact abstracts@easd.org

KEYWORDS

One keyword from the list below must be selected for the submission: 

GROUP 1: Genetics/Epidemiology

01 Epidemiology

02 Genetics of type 1 diabetes

03 Genetics of type 2 diabetes

04 Monogenic forms of diabetes

05 Environmental factors (viruses, nutrients, toxins)

06 Prediction and prevention of type 1 diabetes

07 Prediction of type 2 diabetes

GROUP 2: Islets/Transplantation/ Immunology type 1 diabetes

08 Developmental biology, pancreas

09 Stem cells and beta cell generation

10 Transcriptional regulation and protein synthesis, pancreas

11 Insulin secretion in vitro and exocytosis

12 Beta cell signal transduction

13 Beta cell damage, degeneration and apoptosis

14 Experimental immunology and animal models of type 1 diabetes

15 Clinical immunology

16 Inflammatory mediators in the pathogenesis of type 1 diabetes

17 Pancreas and islet transplantation

GROUP 3: Pathophysiology/Metabolism I

18 Insulin action

19 Insulin sensitivity and resistance

20 Insulin secretion in vivo

21 Hypoglycaemia

22 Gastro-entero pancreatic factors

23 Other hormones

24 Glucose transport

25 Carbohydrate metabolism

26 Protein metabolism

27 Exercise physiology

GROUP 4: Pathophysiology/Metabolism II

28 Inflammation in type 2 diabetes

29 Animal models of type 2 diabetes

30 Lipid metabolism

31 Adipose tissue biology and adipocytokines

32 Inflammation in obesity

33 Animal models of obesity

34 Weight regulation and obesity

35 Brain metabolism

36 Cancer

GROUP 5: Clinical Science and Care I 

37 Diabetes in childhood

38 Nutrition and diet

39 Oral therapies – secretagogues

40 Oral therapies: metformin, sensitisers and other non-secretagogues

41 Oral therapies: novel agents

42 Incretin based therapies

43 Prevention of type 2 diabetes

GROUP 6: Clinical Science and Care II

44 Insulin therapy

45 Devices

46 Health care delivery

47 Education

48 Psychological aspects

49 Socio-economic aspects

GROUP 7: Complications I

50 Pregnancy/complications I

51 Neuropathy - somatic

52 Neuropathy - autonomic, incl. erectile dysfunction

53 Diabetic foot and skin disorders

54 Retinopathy

55 Nephropathy

56 Hypertension

GROUP 8: Complications II 

57 Cardiac complications

58 Macrovascular disease

59 Pathogenic mechanisms/complications

60 Dyslipidaemia, lipoproteins

61 Endothelium

62 Animal models with complications

63 Other complications

“RISING STAR SYMPOSIUM”

The “Rising Star Symposium” aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at the 47th EASD Annual Meeting. Four candidates will be selected, two in basic research and two in clinical research. Selected candidates will be invited by EASD to present a lecture (25 minute lecture + 5 minute discussion) and will receive a commemorative diploma. EASD will cover travel expenses, hotel and registration costs for the selected scientists.

Candidates for the “Rising Star Symposium” must be paid-up members of EASD and have a PhD, MD or equivalent degree. The candidates must be under the age of 38 on 01 January 2011. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

The application to deliver a lecture at the “Rising Star Symposium” must include:

a.  A two-page description of the applicant’s research line, including supporting references to his/her publications, where appropriate.

b.  Full name, address, date of birth and brief curriculum vitae of the applicant (two pages maximum), plus complete list of publications.

c.  Proof of current EASD membership.

d.  Date and nature of the present appointment held by applicant.

e.  Letter of recommendation from the Head of the Department.

f.   Statement on whether the candidate wishes to apply in basic or clinical research (the basic and clinical tracks are evaluated separately). 

The Deadline for applications is 20 February 2011. Applicants will be informed of the outcome of their application by the end of May 2011.